BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19277049)

  • 1. Role of autologous and allogeneic stem cell transplantation in myeloma.
    Bensinger WI
    Leukemia; 2009 Mar; 23(3):442-8. PubMed ID: 19277049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?
    Bensinger WI
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):783-95. PubMed ID: 18070719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
    Nishihori T; Alsina M
    Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
    Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current status of hematopoietic stem cell transplantation for multiple myeloma.
    Bensinger WI
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
    Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A; Sonneveld P; Goldschmidt H; Jagannath S; Barlogie B; Mateos M; Gimsing P; Sezer O; Mikhael J; Lu J; Dimopoulos M; Mazumder A; Palumbo A; Abonour R; Anderson K; Attal M; Blade J; Bird J; Cavo M; Comenzo R; de la Rubia J; Einsele H; Garcia-Sanz R; Hillengass J; Holstein S; Johnsen HE; Joshua D; Koehne G; Kumar S; Kyle R; Leleu X; Lonial S; Ludwig H; Nahi H; Nooka A; Orlowski R; Rajkumar V; Reiman A; Richardson P; Riva E; San Miguel J; Turreson I; Usmani S; Vesole D; Bensinger W; Qazilbash M; Efebera Y; Mohty M; Gasparreto C; Gajewski J; LeMaistre CF; Bredeson C; Moreau P; Pasquini M; Kroeger N; Stadtmauer E
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2039-2051. PubMed ID: 26428082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
    Kneppers E; van der Holt B; Kersten MJ; Zweegman S; Meijer E; Huls G; Cornelissen JJ; Janssen JJ; Huisman C; Cornelisse PB; Bruijnen CP; Emmelot M; Sonneveld P; Lokhorst HM; Mutis T; Minnema MC
    Blood; 2011 Sep; 118(9):2413-9. PubMed ID: 21690556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma.
    Nishihori T; Kharfan-Dabaja MA; Ochoa-Bayona JL; Bazarbachi A; Pasquini M; Alsina M
    Hematol Oncol Stem Cell Ther; 2011; 4(1):1-9. PubMed ID: 21460601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
    Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced intensity allogeneic stem cell transplantation in multiple myeloma.
    Bensinger WI
    Front Biosci; 2007 May; 12():4384-92. PubMed ID: 17485382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplantation in multiple myeloma.
    Gahrton G
    Recent Results Cancer Res; 2011; 183():273-84. PubMed ID: 21509689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hematopoietic stem cell transplantation in multiple myeloma].
    Vela-Ojeda J; Ruiz-Esparza MA
    Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
    Vesole DH; Simic A; Lazarus HM
    Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?
    Giralt S; Koehne G
    Curr Hematol Malig Rep; 2013 Dec; 8(4):284-90. PubMed ID: 24146203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation in multiple myeloma.
    Harousseau JL
    J Natl Compr Canc Netw; 2009 Oct; 7(9):961-70. PubMed ID: 19878639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.